Lung Cancer News
The addition of pravastatin to the first-line standard of care failed to provide benefit for patients with small-cell lung cancer (SCLC).
Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with non-small cell lung cancer (NSCLC).
No significant difference in overall survival between afatinib and gefitinib among patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).
Only 262,700 of the eligible 6.8 million smokers or ex-smokers underwent LDCT in 2015.
Chemoradiotherapy with etoposide plus cisplatin may improve overall survival over weekly paclitaxel plus carboplatin.
Adding bevacizumab to both for the first-line treatment of extensive-disease small cell lung cancer (SCLC) improved progression-free survival, but not overall survival.
Stereotactic radiosurgery followed by erlotinib is efficacious for treating patients with non-small cell lung cancer (NSCLC).
Being of African American or Caucasian descent does not determine the likelihood of genomic mutations in a lung tumor.
Cardiac events were relatively common following high-dose thoracic radiotherapy among patients with stage III non-small cell lung cancer (NSCLC).
The proportion of patients with untreated stage IIIA or IV non-small cell lung cancer (NSCLC) is rising despite superior outcomes.
Lung cancer screening programs may be improved with the use of risk prediction models that incorporate lung function.
The FDA has granted Priority Review to Merck's sBLA for pembrolizumab (Keytruda) in combination with chemotherapy.
Timing of adjuvant chemotherapy after a patient undergoes resection for non-small cell lung cancer (NSCLC) may be a factor of overall survival.
Nivolumab monotherapy and combined with ipilimumab shows encouraging response among patients with small cell lung cancer (SCLC).
For patients being treated for stage 3 NSCLC, cisplatin-etoposide or carboplatin-paclitaxel demonstrate comparable efficacy.
Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable toxicity profile.
PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.
Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).
Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC
Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).
Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC
First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible
- Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future
- NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib